This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PBT | |
|---|---|
| Name | PBT |
| Other names | Phenylbutazone (common historical), Persistent Bioaccumulative Toxicant (alternative context) |
| Type | Veterinary anti-inflammatory; environmental hazard classification |
| Formula | C19H20N2O2 (for phenylbutazone) |
| CAS number | 50-33-9 |
| Melting point | 121–122 °C |
PBT
PBT is a three-letter abbreviation used in distinct contexts: historically for the nonsteroidal anti-inflammatory drug phenylbutazone and in environmental science for the class of chemicals designated as persistent, bioaccumulative, and toxic. In pharmacology, the substance emerged as an analgesic and anti-inflammatory agent in human and veterinary medicine. In toxicology and environmental regulation, PBT denotes a criterion guiding hazard assessment for industrial chemicals, pesticides, and organic pollutants.
In clinical literature the acronym refers to phenylbutazone, a member of the pyrazolone class alongside Aminopyrine, Antipyrine, Mesocarb and related compounds used in the 20th century. In regulatory and environmental chemistry the term PBT is a hazard classification alongside vPvB, Endocrine disruptor and Persistent organic pollutant frameworks used by agencies such as the United States Environmental Protection Agency, the European Chemicals Agency, and the Stockholm Convention decision-making. Other specialized abbreviations (e.g., PBDE for polybrominated diphenyl ethers) are distinct but conceptually related to the PBT criteria employed by the Organisation for Economic Co-operation and Development and the United Nations Environment Programme.
Phenylbutazone was synthesized in the 1940s and entered clinical use in the 1950s, contemporaneous with drugs like Indomethacin, Aspirin, and Diclofenac. It became widely used in human medicine for rheumatologic conditions alongside the rise of anti-inflammatories in the mid-20th century, later shifting primarily to veterinary practice with notable applications in equine medicine during decades when agents such as Flunixin and Ketoprofen were also in use. The environmental PBT concept developed in parallel with growing regulatory attention to compounds like DDT, PCBs, and Dioxins; international instruments such as the Stockholm Convention on Persistent Organic Pollutants and policy initiatives by the European Union formalized PBT screening criteria in the late 20th and early 21st centuries.
Phenylbutazone acts as a nonselective inhibitor of cyclooxygenase enzymes similar in target profile to other NSAIDs such as Ibuprofen and Naproxen, reducing prostaglandin synthesis and thereby inflammation and pain. Its pharmacokinetics include hepatic metabolism with biotransformation pathways involving cytochrome P450 isoforms familiar from interactions with agents like Warfarin and Phenytoin. Adverse hematologic mechanisms—reported with phenylbutazone—include idiosyncratic marrow suppression and aplastic anemia, mechanisms also implicated in hypersensitivity syndromes observed with drugs such as Chloramphenicol and Sulfonamides.
When the acronym denotes persistent, bioaccumulative, and toxic chemicals, the mechanistic concerns are ecological and biochemical: persistence corresponds to resistance to degradation processes exemplified by DDT and PCBs; bioaccumulation involves trophic magnification observed in food webs studied in locations like the Great Lakes and the Arctic; toxicity encompasses endocrine, reproductive, neurodevelopmental, and carcinogenic outcomes similar to those documented for Mercury and Lead exposures.
Phenylbutazone was historically administered orally or parenterally for conditions such as ankylosing spondylitis and rheumatoid arthritis, with dosing strategies paralleling those used for other mid-century anti-inflammatories such as indomethacin regimens. Veterinary administration—especially in horses—has included oral paste, tablet, and injectable formulations, with monitoring protocols comparable to those recommended for Flunixin meglumine and Phenylbutazone alternatives in equine practice. Clinical use diminished in human medicine due to safety concerns and regulatory actions similar to withdrawals of drugs like Tegaserod and restrictions seen with Thalidomide-era reforms.
Phenylbutazone’s human safety profile includes serious hematologic adverse events (aplastic anemia), hypersensitivity, and gastrointestinal ulceration—risks paralleling those prompting caution for agents like Aspirin in vulnerable populations. In animals, concerns include NSAID-associated renal and gastrointestinal effects and residues in food-producing species raising public health questions akin to debates around residues of Chloramphenicol and Nitrofurans. The PBT hazard designation implicates long-range transport and ecosystem effects; well-studied examples with similar profiles include PFOS, PCBs, and Mirex, each associated with biomagnification and chronic toxicity in wildlife and humans.
Phenylbutazone has been withdrawn or restricted for human use in many jurisdictions by agencies such as the Food and Drug Administration and the European Medicines Agency, while veterinary use remains regulated with species- and residue-based limits enforced by authorities like the United States Department of Agriculture and national veterinary boards. The PBT hazard criteria are embedded in regulatory schemes including the REACH Regulation of the European Union, risk assessment guidance from the Organisation for Economic Co-operation and Development, and listing processes under the Stockholm Convention, guiding control, substitution, and phase-out measures.
Contemporary research addresses safer anti-inflammatory alternatives and pharmacogenomic predictors of adverse reactions, paralleling investigations into drug safety exemplified by studies on Warfarin pharmacogenetics and Abacavir hypersensitivity. Environmental science research focuses on detection methods, degradation technologies (bioremediation strategies similar to those applied to PCBs), alternative chemical design following green chemistry principles promoted by institutes like the American Chemical Society and the Royal Society of Chemistry, and policy debates over acceptable risk thresholds as seen in controversies surrounding Glyphosate and Neonicotinoids.
Category:Pharmacology Category:Environmental toxicology